Clinical trials: Endometrial Carcinoma
Uterine Cervical Neoplasms, Endometrial Neoplasms Malignant
Adjuvant Protontherapy of Cervical and Endometrial Carcinomas
The APROVE study is a prospective single-center single-arm phase-II study. Patients with cervical or endometrial cancer after surgical resection who have an indication for postoperative pelvic radiotherapy will be treated with…
- Trial name
- APROVE (NCT03184350)
- Testing
- Adjuvant pelvic proton radiation
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Heidelberg University
Recurrent Endometrial Carcinoma
Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer
This phase II trial is studying how well bevacizumab works in treating patients with recurrent or persistent endometrial cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00301964
- Testing
- bevacizumab, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Cancer, Perioperative Complication
Iron Prehabilitation in Endometrial Cancer
Endometrial cancer patients often have iron deficiency anemia before surgery, which can be effectively treated with oral iron supplementation.
- Conditions
- Endometrial Cancer, Perioperative Complication, Prehabilitation
- Trial name
- IROGYN (NCT06049693)
- Testing
- Ferrous Gluconate 300 MG
- Where
- Greece
- Volunteers
- 156 people
- Sponsor
- National and Kapodistrian University of Athens
Endometrial Adenocarcinoma, Recurrent Uterine Corpus Carcinoma
Prognostic Biomarkers in Patients With Endometrial Cancer
This research study is studying prognostic biomarkers in tissue samples from patients with endometrial cancer. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that…
- Conditions
- Endometrial Adenocarcinoma, Recurrent Uterine Corpus Carcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer
- Trial name
- NCT01208467
- Testing
- Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 2,824 people
- Sponsor
- Gynecologic Oncology Group
Ovarian Cancer, Fallopian Tube Cancer
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
This study is researching an investigational drug called REGN5668 : alone or, combined with cemiplimab (also known as REGN2810) or, combined with both cemiplimab and fianlimab (also known as REGN3767), or combined with ubamatamab…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer
- Trial name
- NCT04590326
- Testing
- REGN5668, Cemiplimab, Ubamatamab
- Where
- 28 sites in United States, Belgium and 3 more
- Volunteers
- 612 people
- Sponsor
- Regeneron Pharmaceuticals
Prostate Cancer, Salivary Gland Cancer
A Clinical Trial to Determine the Most Suitable Dose of OPB-111001 in Patients With Advanced Cancer
The purpose of this study is to determine the tolerability profile of OPB-111001 and to determine the most suitable dose of OPB-111001 in patients with advanced cancer
- Conditions
- Prostate Cancer, Salivary Gland Cancer, Endometrial Cancer, Squamous Cell Carcinoma of the Cervix
- Trial name
- NCT02042885
- Testing
- OPB-111001
- Where
- 2 sites in United Kingdom
- Volunteers
- 79 people
- Sponsor
- Otsuka Novel Products GmbH
Endometrial Cancer, Ovarian Cancer
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid…
- Conditions
- Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent
- Trial name
- NCT07444814
- Testing
- HWK-007
- Where
- 12 sites in United States
- Volunteers
- 226 people
- Sponsor
- Whitehawk Therapeutics, Inc.
Endometrial Cancer
A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer
The primary purpose of this study is to investigate whether administration of ixabepilone results in superior outcome as assessed by overall survival compared with that achieved with standard chemotherapy (paclitaxel or…
- Trial name
- IXAMPLE2 (NCT00883116)
- Testing
- Ixabepilone, Doxorubicin, Paclitaxel
- Where
- 93 sites in United States, Argentina and 17 more
- Volunteers
- 551 people
- Sponsor
- R-Pharm
Endometrial Cancer, Adjuvant Radiotherapy
Study of Early Stage Endometrial Cancer Based on Molecular Classification and Traditional Risk Stratification to Guide Adjuvant Radiotherapy Decisions
The purpose of this study is to compare the efficacy and toxicity of early stage endometrial cancer based on molecular classification and conventional risk stratification adjuvant therapy decision-making, and to provide…
- Conditions
- Endometrial Cancer, Adjuvant Radiotherapy, Molecular Classification
- Trial name
- NCT05524389
- Testing
- Vaginal brachytherapy, Pelvic external beam radiotherapy, Observation
- Volunteers
- 624 people
- Sponsor
- Peking Union Medical College Hospital
Adenomyosis, Endometrial Cancer
Multi-omics Study on the Pathogenesis of Malignant Transformation of Adenomyosis
This study is to explore the driving genes and the molecular mechanism of malignant transformation of adenomyosis. This study acquired the formalin fixed paraffin-embedded (FFPE) tissue of patients pathologically conformed…
- Conditions
- Adenomyosis, Endometrial Cancer, Ectopic Endometrial Tissue, Eutopic Endometrium
- Trial name
- NCT04010487
- Testing
- whole exome sequencing and RNA-sequencing
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Lei Li
Endometrial Carcinoma
A Study of GDC-0980 in the Treatment of Recurrent or Persistent Endometrial Carcinoma
This is a multicenter, single-arm, open-label Phase II study to evaluate the activity of GDC-0980 in patients with recurrent or persistent endometrial cancer.
- Trial name
- NCT01455493
- Testing
- GDC-0980
- Where
- 28 sites in United States
- Volunteers
- 56 people
- Sponsor
- Genentech, Inc.
Laparoscopic Hysterectomy and Sentinel Lymph Node Biopsy
Complications of Laparoscopic Hysterectomy and Sentinel Lymph Node Biopsy for Endometrial Carcinoma
Endometrial adenocarcinoma is believed to be a more treatable malignancy. Poor prognosis is associated with age, grade and depth of myometrial invasion, lymph node status, tumor size, invasion of lymphovascular space and…
- Trial name
- NCT04894552
- Testing
- Laparoscopic Hysterectomy and Sentinel Lymph Node Biopsy for Endometrial Carcinoma
- Where
- Egypt
- Volunteers
- 20 people
- Sponsor
- Ain Shams Maternity Hospital
Breast Cancer, Endometrial Cancer
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway…
- Conditions
- Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma
- Trial name
- NCT07109726
- Testing
- TER-2013, Fulvestrant injection
- Where
- 25 sites in United States, Ireland and 3 more
- Volunteers
- 248 people
- Sponsor
- Terremoto Biosciences Inc.
Endometrial Cancer
Laparoscopic Approach to Cancer of the Endometrium
The primary objective of this study is to assess disease-free survival at 4.5 years postoperatively for women with apparent Stage 1 endometrial cancer, comparing patients who are randomised to receive Total Laparoscopic…
- Trial name
- NCT00096408
- Testing
- Total Abdominal Hysterectomy, Total Laparoscopic Hysterectomy
- Where
- 23 sites in Australia, Hong Kong and 2 more
- Volunteers
- 760 people
- Sponsor
- Queensland Centre for Gynaecological Cancer
Endometrial Neoplasms
Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer
This is a non-randomized, single arm, multi-center, phase II study of pembrolizumab in combination with doxorubicin in subjects with recurrent/metastatic endometrial cancer.
- Trial name
- TOPIC (NCT03276013)
- Testing
- Pembrolizumab
- Where
- 7 sites in Spain
- Volunteers
- 48 people
- Sponsor
- Vall d'Hebron Institute of Oncology
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
Infertility Survey Among Reproductive Age Women With Gynecological and Breast Cancer
This study develops infertility survey among reproductive age women with gynecological and breast cancer. This study aims to learn how women consider whether or not to try to have a baby after surviving cancer.
- Conditions
- Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8
- Trial name
- NCT04678414
- Testing
- Healthcare Activity, Survey Administration
- Where
- United States
- Volunteers
- 1,410 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumors, Colorectal Cancer
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
The main purpose of this 3-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.
- Conditions
- Solid Tumors, Colorectal Cancer, Breast Cancer, Ovarian Cancer
- Trial name
- NCT02632448
- Testing
- LY2880070, Gemcitabine
- Where
- 16 sites in United States, Canada and 2 more
- Volunteers
- 229 people
- Sponsor
- Esperas Pharma Inc.
Endometrial Cancer
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
The researchers are doing this study to find out whether elacestrant is an effective and safe treatment alone or in combination with abemaciclib for people with advanced or recurrent ER+ endometrial cancer.
- Trial name
- NCT07209449
- Testing
- Abemaciclib, Elacestrant
- Where
- 7 sites in United States
- Volunteers
- 75 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
NSCLC (Non-small Cell Lung Cancer), HNSCC
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects with Select Advanced Solid Tumors.
- Conditions
- NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer
- Trial name
- NCT07814248
- Testing
- TS-104
- Where
- 3 sites in United States
- Volunteers
- 74 people
- Sponsor
- TwoStep Therapeutics, Inc.
Endometrial Cancer
Human Epididymis Protein 4 in Endometrial Carcinoma
Endometrial cancer represents the most common gynecologic cancer, and it is expected to become an even greater public health concern as the prevalence of obesity, one of the most common risk factors for endometrial cancer…
- Trial name
- NCT03456791
- Testing
- Human epididymis protein 4
- Where
- Egypt
- Volunteers
- 84 people
- Sponsor
- Ain Shams University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.